한국어
English
日本語
中文(简体)Aqvta Tablet 10 mg (Atozepant Dihydrate)
10.3mg
Tablet · Prescription medication
AbbVie Korea Co., Ltd.
Atozepant dihydrate is an analgesic ingredient used for the prevention of migraines.
MFDS ingredient code M284037
Atozepant dihydrate is a neuromodulatory analgesic agent developed for the prevention of migraines. It works by blocking calcitonin gene-related peptide (CGRP) receptors to reduce the frequency of migraine occurrences. It is mainly prescribed for patients with chronic or recurrent migraines.
Atozepant dihydrate blocks the action of calcitonin gene-related peptide (CGRP), a neurotransmitter responsible for triggering migraines in the brain. This reduces vascular dilation and inflammatory responses, thereby preventing the occurrence of migraines. In other words, it alleviates symptoms by blocking the causative signals of migraines.
Approved uses differ by product. Check each product's information for its actual use.
Unlike traditional migraine treatments, Atozepant dihydrate is an oral CGRP receptor antagonist that can be taken in tablet form rather than as an injection. This ingredient is specialized for migraine prevention and is characterized by directly blocking the mechanisms that cause migraines, which is different from other analgesics.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.
